Bioaffinity Technologies, Stock Total Debt
| BIAF Stock | USD 0.68 0.01 0.74% |
bioAffinity Technologies, fundamentals help investors to digest information that contributes to BioAffinity Technologies,'s financial success or failures. It also enables traders to predict the movement of BioAffinity Stock. The fundamental analysis module provides a way to measure BioAffinity Technologies,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioAffinity Technologies, stock.
The BioAffinity Technologies,'s current Total Debt To Capitalization is estimated to increase to 0.23. BioAffinity | Total Debt |
bioAffinity Technologies, Company Total Debt Analysis
BioAffinity Technologies,'s Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current BioAffinity Technologies, Total Debt | 1.58 M |
Most of BioAffinity Technologies,'s fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, bioAffinity Technologies, is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
BioAffinity Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for BioAffinity Technologies, is extremely important. It helps to project a fair market value of BioAffinity Stock properly, considering its historical fundamentals such as Total Debt. Since BioAffinity Technologies,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BioAffinity Technologies,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BioAffinity Technologies,'s interrelated accounts and indicators.
Click cells to compare fundamentals
BioAffinity Total Debt Historical Pattern
Today, most investors in BioAffinity Technologies, Stock are looking for potential investment opportunities by analyzing not only static indicators but also various BioAffinity Technologies,'s growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of BioAffinity Technologies, total debt as a starting point in their analysis.
BioAffinity Technologies, Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
BioAffinity Short Long Term Debt Total
Short Long Term Debt Total |
|
Based on the latest financial disclosure, bioAffinity Technologies, has a Total Debt of 1.58 M. This is 99.94% lower than that of the Biotechnology sector and 99.83% lower than that of the Health Care industry. The total debt for all United States stocks is 99.97% higher than that of the company.
BioAffinity Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioAffinity Technologies,'s direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioAffinity Technologies, could also be used in its relative valuation, which is a method of valuing BioAffinity Technologies, by comparing valuation metrics of similar companies.BioAffinity Technologies, is currently under evaluation in total debt category among its peers.
BioAffinity Technologies, Institutional Holders
Institutional Holdings refers to the ownership stake in BioAffinity Technologies, that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of BioAffinity Technologies,'s outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing BioAffinity Technologies,'s value.| Shares | Clear Street Llc | 2024-09-30 | 100.0 | Bank Of America Corp | 2024-09-30 | 67.0 | Jpmorgan Chase & Co | 2024-09-30 | 21.0 | Ground Swell Capital, Llc | 2024-09-30 | 0.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Ubs Group Ag | 2024-09-30 | 0.0 | Renaissance Technologies Corp | 2024-09-30 | 0.0 | Qube Research & Technologies | 2024-09-30 | 0.0 | Cypress Capital, Llc | 2024-09-30 | 0.0 | Vanguard Group Inc | 2024-09-30 | 260.9 K | Geode Capital Management, Llc | 2024-09-30 | 87.2 K |
BioAffinity Fundamentals
| Return On Equity | -1.52 | ||||
| Return On Asset | -0.7 | ||||
| Profit Margin | (1.19) % | ||||
| Operating Margin | (0.87) % | ||||
| Current Valuation | 11.48 M | ||||
| Shares Outstanding | 15.48 M | ||||
| Shares Owned By Insiders | 29.55 % | ||||
| Shares Owned By Institutions | 2.46 % | ||||
| Number Of Shares Shorted | 114.04 K | ||||
| Price To Book | 3.37 X | ||||
| Price To Sales | 1.44 X | ||||
| Revenue | 2.53 M | ||||
| EBITDA | (7.63 M) | ||||
| Net Income | (7.94 M) | ||||
| Cash And Equivalents | 214.4 K | ||||
| Cash Per Share | 0.08 X | ||||
| Total Debt | 1.58 M | ||||
| Current Ratio | 0.02 X | ||||
| Book Value Per Share | 0.30 X | ||||
| Cash Flow From Operations | (6.04 M) | ||||
| Short Ratio | 1.43 X | ||||
| Earnings Per Share | (0.91) X | ||||
| Target Price | 6.0 | ||||
| Number Of Employees | 75 | ||||
| Beta | 3.12 | ||||
| Market Capitalization | 19.81 M | ||||
| Total Asset | 8.22 M | ||||
| Retained Earnings | (44.6 M) | ||||
| Working Capital | 1.72 M | ||||
| Net Asset | 8.22 M |
About BioAffinity Technologies, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze bioAffinity Technologies,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioAffinity Technologies, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of bioAffinity Technologies, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether bioAffinity Technologies, is a strong investment it is important to analyze BioAffinity Technologies,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact BioAffinity Technologies,'s future performance. For an informed investment choice regarding BioAffinity Stock, refer to the following important reports:Check out BioAffinity Technologies, Piotroski F Score and BioAffinity Technologies, Altman Z Score analysis. For more detail on how to invest in BioAffinity Stock please use our How to Invest in BioAffinity Technologies, guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioAffinity Technologies,. If investors know BioAffinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioAffinity Technologies, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share | Quarterly Revenue Growth 120.474 | Return On Assets | Return On Equity |
The market value of bioAffinity Technologies, is measured differently than its book value, which is the value of BioAffinity that is recorded on the company's balance sheet. Investors also form their own opinion of BioAffinity Technologies,'s value that differs from its market value or its book value, called intrinsic value, which is BioAffinity Technologies,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioAffinity Technologies,'s market value can be influenced by many factors that don't directly affect BioAffinity Technologies,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioAffinity Technologies,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if BioAffinity Technologies, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioAffinity Technologies,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.